Search results for: Market Access
Filter search results
Patrick Holmes
3 February 2023
…policy issues supporting Pfizer’s R&D-driven organization, including driving affordable patient access to medicines, while allowing the company to continue to develop and deliver innovative treatments. Issue areas include market-based R&D…
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
…incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used. Key takeaways The market for antibiotics is failing…
Around The World in HTAs: The Slovak Republic – Valuing the Future
13 September 2023
…illustrates the process for outpatient drugs. The pharmaceutical company first obtains marketing authorization from either the European Medicines Agency (EMA) or the Slovak Republic State Institute for Drug Control (SIDC)….
Julia Toth
19 September 2023
Julia Toth joined OHE in August 2023 and leads digital marketing across social media, email campaigns, paid advertising, and events. She promotes OHE’s research, reports, and webinars to health economists,…
What is the future of health economics?
1 May 2023
…since 2012 because no one at national level owned the policy and left it to the will of the market Richard Murray, Chief Executive Officer at The King’s Fund Richard…
The Impact of Price-cap Regulations on Entry and Exit by Generic Pharmaceutical Firms in Canada
23 February 2015, 12:00am
OHE Lunchtime Seminar with Professor Aslam H. Anis, University of British Columbia Pharmaceutical markets Canada are unique in that generic drugs are subject to ‘price-cap’ regulations set by provincial governments. …
Measuring Value with Pharmacoeconomics
26 May 2011
…health technologies, granting the new medicine or device market access on condition that further research into its costs and effectiveness is completed. As with all uses of scarce resources, CEA…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
…NICE assesses the value of a health technology is scheduled to be completed in June 2014. In a presentation at the PharmaAccess Leader’s Forum, Martin Garau summarised the proposed changes…
OHE Lunchtime Seminar on 23 February 2015: The Impact of Price-cap Regulations on Entry and Exit by Generic Pharmaceutical Firms in Canada
22 January 2015
…February, Professor Aslam H. Anis will lead an OHE Seminar on The impact of price-cap regulations on entry and exit by generic pharmaceutical firms in Canada. Pharmaceutical markets Canada…